Literature DB >> 34387840

Prevalence of low skeletal muscle quantity and quality and their associated factors in patients before allogeneic hematopoietic stem cell transplantation.

Shinya Yoshida1, Goro Sakurai2, Tetsutaro Yahata2.   

Abstract

Both quality and quantity of skeletal muscle are considered important for prognostic factors and clinical outcomes in solid cancers. However, few studies have examined both quality and quantity of skeletal muscle in patients with hematological malignancies. The aim of the present study was to clarify the prevalence of low skeletal muscle quantity and quality and their associated factors in patients before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Pretransplant plain CT imaging at the third lumber vertebra level was used to measure the psoas muscle mass index (PMI) and the intramuscular adipose tissue content (IMAC) in 113 adult patients (age 47.1 ± 14.6 years) before HSCT. We analyzed the factors associated with PMI and IMAC, respectively. Although 62.8% of all patients had low skeletal muscle mass, only 8% had poor skeletal muscle quality. Multivariable logistic analysis showed that older age [odds ratio (OR) = 2.45, confidence interval (CI) = 1.04-5.76, P = 0.04], male (OR = 4.35, CI = 0.05-0.97, P = 0.04), and low BMI (OR = 0.83, CI = 0.71-0.97, P = 0.02) were independent risk factors for low PMI before HSCT. Only age (≤ 50 years) was significantly associated with muscle quality (modified OR = 0.07, CI = 0.00-0.43, P < 0.01) in univariate analysis. Most patients already showed low skeletal muscle mass before allo-HSCT although skeletal muscle quality was relatively preserved. These results may be indicative of pre-cachexia and may be useful for its long-term management in allo-HSCT patients.
© 2021. Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Intramuscular adipose tissue content; Psoas muscle mass index

Mesh:

Year:  2021        PMID: 34387840     DOI: 10.1007/s11739-021-02828-3

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  26 in total

1.  Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.

Authors:  Taiki Ando; Shin Fujisawa; Haruka Teshigawara; Ayako Matsumura; Takayuki Sakuma; Taisei Suzuki; Hiroshi Teranaka; Eriko Ogusa; Yoshimi Ishii; Kazuho Miyashita; Hiroyuki Takahashi; Yuki Nakajima; Takuya Miyazaki; Maki Hagihara; Kenji Matsumoto; Etsuko Yamazaki; Hideaki Nakajima
Journal:  Int J Hematol       Date:  2020-05-25       Impact factor: 2.490

2.  Prevalence and related factors of sarcopenia in newly diagnosed cancer patients.

Authors:  Utku Oflazoglu; Ahmet Alacacioglu; Umut Varol; Yuksel Kucukzeybek; Tarik Salman; Halil Taskaynatan; Yasar Yildiz; Ozlem Ozdemir; MustafaOktay Tarhan
Journal:  Support Care Cancer       Date:  2019-06-03       Impact factor: 3.603

3.  Sarcopenia is associated with autologous transplant-related outcomes in patients with lymphoma.

Authors:  Megan V Caram; Emily L Bellile; Michael J Englesbe; Michael Terjimanian; Stewart C Wang; Jennifer J Griggs; Daniel Couriel
Journal:  Leuk Lymphoma       Date:  2015-06-18

4.  Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Saro H Armenian; Meisi Xiao; Jennifer Berano Teh; Brandyn Lee; Howard A Chang; Kristen Mascarenhas; Sean Lee; Alex Iukuridze; Jack J Xie; Jessica M Scott; Lee W Jones; F Lennie Wong; Stephen J Forman; Ryotaro Nakamura
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

5.  Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study.

Authors:  Dong-Dong Huang; Xiao-Xi Chen; Xi-Yi Chen; Su-Lin Wang; Xian Shen; Xiao-Lei Chen; Zhen Yu; Cheng-Le Zhuang
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-29       Impact factor: 4.553

6.  Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy.

Authors:  Yasunari Fukuda; Kazuyoshi Yamamoto; Motohiro Hirao; Kazuhiro Nishikawa; Yukiko Nagatsuma; Tamaki Nakayama; Sugano Tanikawa; Sakae Maeda; Mamoru Uemura; Masakazu Miyake; Naoki Hama; Atsushi Miyamoto; Masataka Ikeda; Shoji Nakamori; Mitsugu Sekimoto; Kazumasa Fujitani; Toshimasa Tsujinaka
Journal:  Gastric Cancer       Date:  2015-09-25       Impact factor: 7.370

7.  Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.

Authors:  Michael P Chu; Jessica Lieffers; Sunita Ghosh; Andrew R Belch; Neil S Chua; Amelie Fontaine; Randeep Sangha; A Robert Turner; Vickie E Baracos; Michael B Sawyer
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

8.  Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Se-Il Go; Mi Jung Park; Haa-Na Song; Hoon-Gu Kim; Myoung Hee Kang; Hyang Rae Lee; Yire Kim; Rock Bum Kim; Soon Il Lee; Gyeong-Won Lee
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-04-12       Impact factor: 12.910

9.  Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy.

Authors:  Michael P Chu; Jessica Lieffers; Sunita Ghosh; Andrew Belch; Neil S Chua; Amelie Fontaine; Randeep Sangha; Robert A Turner; Vickie E Baracos; Michael B Sawyer
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-11-21       Impact factor: 12.910

10.  Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study.

Authors:  Takayuki Shiroyama; Izumi Nagatomo; Shohei Koyama; Haruhiko Hirata; Sumiyuki Nishida; Kotaro Miyake; Kiyoharu Fukushima; Yuya Shirai; Yuichi Mitsui; So Takata; Kentaro Masuhiro; Moto Yaga; Kota Iwahori; Yoshito Takeda; Hiroshi Kida; Atsushi Kumanogoh
Journal:  Sci Rep       Date:  2019-02-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.